Verona Pharma
🇬🇧United Kingdom
- Country
- 🇬🇧United Kingdom
- Ownership
- Public
- Established
- 2005-01-01
- Employees
- 79
- Market Cap
- -
- Website
- http://www.veronapharma.com
- Introduction
Verona Pharma Plc engages in the development and commercialization of therapeutics for the treatment of respiratory diseases. It focuses on developing inhaled ensifentrine for the maintenance treatment of chronic obstructive pulmonary disease. The company was founded by Michael J. A. Walker and Clive P. Page on February 24, 2005 and is headquartered in London, the United Kingdom.
Dose Ranging Study of RPL554 in Chronic Obstructive Pulmonary Disease (COPD) Patients
- First Posted Date
- 2018-02-23
- Last Posted Date
- 2019-06-04
- Lead Sponsor
- Verona Pharma plc
- Target Recruit Count
- 405
- Registration Number
- NCT03443414
- Locations
- 🇧🇬
Medical Center Nov, Stara Zagora, Bulgaria
🇧🇬Fifth MHAT - Sofia EAD, Sofia, Bulgaria
🇩🇪emovis GmbH, Berlin, Germany
The Effects of RPL554 in Addition to Tiotropium in COPD Patients
Phase 2
Completed
- Conditions
- Interventions
- First Posted Date
- 2017-01-23
- Last Posted Date
- 2019-02-27
- Lead Sponsor
- Verona Pharma plc
- Target Recruit Count
- 30
- Registration Number
- NCT03028142
A Study of RPL554 in Patients With Cystic Fibrosis
- First Posted Date
- 2016-09-30
- Last Posted Date
- 2024-05-21
- Lead Sponsor
- Verona Pharma plc
- Target Recruit Count
- 10
- Registration Number
- NCT02919995
- Locations
- 🇬🇧
Papworth Hospital, Cambridge, United Kingdom
The Effects of RPL554 on Top of Standard COPD Reliever Medications
- First Posted Date
- 2015-09-04
- Last Posted Date
- 2016-09-09
- Lead Sponsor
- Verona Pharma plc
- Target Recruit Count
- 36
- Registration Number
- NCT02542254
- Locations
- 🇬🇧
Medicines Evaluation Unit, Manchester, United Kingdom
Comparison of RPL554 With Placebo and Salbutamol in Asthmatic Patients
- First Posted Date
- 2015-04-27
- Last Posted Date
- 2016-09-09
- Lead Sponsor
- Verona Pharma plc
- Target Recruit Count
- 29
- Registration Number
- NCT02427165
- Locations
- 🇸🇪
Skane University Hospital, Lund, Sweden
🇬🇧Celerion, Belfast, United Kingdom
SAD/MAD Study of a New Formulation of Nebulised RPL554 in Healthy Subjects and COPD Subjects
Phase 1
Completed
- Conditions
- Interventions
- First Posted Date
- 2014-12-04
- Last Posted Date
- 2015-10-28
- Lead Sponsor
- Verona Pharma plc
- Target Recruit Count
- 112
- Registration Number
- NCT02307162
- Locations
- 🇬🇧
Medicines Evaluation Unit, Manchester, United Kingdom
© Copyright 2024. All Rights Reserved by MedPath